Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling

Cancer Letters

Volumn 350, Issue 1-2, 2014, Pages 43-51

  Chen, Zhangqian ^a   Zhang, Lin ^a   Xia, Limin ^a   Jin, Yangsheng ^b   Wu, Qing ^b   Guo, Hao ^a   Shang, Xin ^a   Dou, Jianhua ^a   Wu, Kaichun ^a   Nie, Yongzhan ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Genechem Co Ltd   (China)

Author keywords

Expression profiling; Gastric cancer; Mechanism; Multidrug resistance; Therapeutic target

Indexed keywords

MESSENGER RNA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE ONTOLOGY; GENETIC REGULATION; GENOMICS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MTT ASSAY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; VALIDATION STUDY;

EXPRESSION PROFILING; GASTRIC CANCER; MECHANISM; MULTIDRUG RESISTANCE; THERAPEUTIC TARGET;

CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENOMICS; HUMANS; MICRORNAS; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84901489950     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.04.010     Document Type: Article

References (46)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Gottesman M.M. Mechanisms of cancer drug resistance. Ann. Rev. Med. 2002, 53:615-627.
3. Wang X., Lan M., Shi Y.Q., Lu J., Zhong Y.X., Wu H.P., Zai H.H., Ding J., Wu K.C., Pan B.R., Jin J.P., Fan D.M. Differential display of vincristine-resistance-related genes in gastric cancer SGC7901 cell. World J Gastroenterol 2002, 8:54-59.
4. Kang H.C., Kim I.J., Park J.H., Shin Y., Ku J.L., Jung M.S., Yoo B.C., Kim H.K., Park J.G. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin. Cancer Res. 2004, 10:272-284.
5. Park J.S., Young Y.S., Kim J.M., Yeom Y.I., Kim Y.S., Kim N.S. Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett. 2004, 214:19-33.
6. Sakamoto M., Kondo A., Kawasaki K., Goto T., Sakamoto H., Miyake K., Koyamatsu Y., Akiya T., Iwabuchi H., Muroya T., Ochiai K., Tanaka T., Kikuchi Y., Tenjin Y. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum. Cell 2001, 14:305-315.
7. Suganuma K., Kubota T., Saikawa Y., Abe S., Otani Y., Furukawa T., Kumai K., Hasegawa H., Watanabe M., Kitajima M., Nakayama H., Okabe H. Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci. 2003, 94:355-359.
8. Yang Y.X., Xiao Z.Q., Chen Z.C., Zhang G.Y., Yi H., Zhang P.F., Li J.L., Zhu G. Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics 2006, 6:2009-2021.
9. Fujita Y., Kojima K., Hamada N., Ohhashi R., Akao Y., Nozawa Y., Deguchi T., Ito M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 2008, 377:114-119.
10. Pogribny I.P., Filkowski J.N., Tryndyak V.P., Golubov A., Shpyleva S.I., Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int. J. Cancer 2010, 127:1785-1794.
11. Tsuchiya Y., Nakajima M., Takagi S., Taniya T., Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006, 66:9090-9098.
12. Xia L., Zhang D., Du R., Pan Y., Zhao L., Sun S., Hong L., Liu J., Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 2008, 123:372-379.
13. Zhu H., Wu H., Liu X., Evans B.R., Medina D.J., Liu C.G., Yang J.M. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 2008, 76:582-588.
14. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
15. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
16. Rajewsky N. MicroRNA target predictions in animals. Nat. Genet. 2006, 38(Suppl):S8-S13.
17. Rai K., Takigawa N., Ito S., Kashihara H., Ichihara E., Yasuda T., Shimizu K., Tanimoto M., Kiura K. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther. 2011, 10:1720-1727.
18. Aprelikova O., Palla J., Hibler B., Yu X., Greer Y.E., Yi M., Stephens R., Maxwell G.L., Jazaeri A., Risinger J.I., Rubin J.S., Niederhuber J. Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene 2013, 32:3246-3253.
19. Ke G., Liang L., Yang J.M., Huang X., Han D., Huang S., Zhao Y., Zha R., He X., Wu X. MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. Oncogene 2013, 32:3019-3027.
20. Li T., Wang H., Sun Y., Zhao L., Gang Y., Guo X., Huang R., Yang Z., Pan Y., Wu K., Xu L., Liu Z., Fan D. Transcription factor CUTL1 is a negative regulator of drug resistance in gastric cancer. J. Biol. Chem. 2013, 288:4135-4147.
21. Du J., Pan Y., Shi Y., Guo C., Jin X., Sun L., Liu N., Qiao T., Fan D. Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int. J. Cancer 2005, 113:213-220.
22. Zhao Y., You H., Liu F., An H., Shi Y., Yu Q., Fan D. Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett. 2002, 185:211-218.
23. Lehne G., Grasmo-Wendler U.H., Berner J.M., Meza-Zepeda L.A., Adamsen B.L., Flack A., Reiner A., Clausen O.P., Hovig E., Myklebost O. Upregulation of stem cell genes in multidrug resistant K562 leukemia cells. Leukemia Res. 2009, 33:1379-1385.
24. Turton N.J., Judah D.J., Riley J., Davies R., Lipson D., Styles J.A., Smith A.G., Gant T.W. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 2001, 20:1300-1306.
25. Januchowski R., Zawierucha P., Andrzejewska M., Rucinski M., Zabel M. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed. Pharmacother. 2013, 67:240-245.
26. Kimura Y., Morita S.Y., Matsuo M., Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 2007, 98:1303-1310.
27. Duan Z., Brakora K.A., Seiden M.V. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol. Cancer Ther. 2004, 3:833-838.
28. Marchini S., Fruscio R., Clivio L., Beltrame L., Porcu L., Nerini I.F., Cavalieri D., Chiorino G., Cattoretti G., Mangioni C., Milani R., Torri V., Romualdi C., Zambelli A., Romano M., Signorelli M., di Giandomenico S., D'Incalci M. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur. J. Cancer 2013, 49:520-530.
29. Rosano L., Cianfrocca R., Spinella F., Di Castro V., Nicotra M.R., Lucidi A., Ferrandina G., Natali P.G., Bagnato A. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin. Cancer Res. 2011, 17:2350-2360.
30. Vandewalle C., Comijn J., De Craene B., Vermassen P., Bruyneel E., Andersen H., Tulchinsky E., Van Roy F., Berx G. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res. 2005, 33:6566-6578.
31. Carver E.A., Jiang R., Lan Y., Oram K.F., Gridley T. The mouse snail gene encodes a key regulator of the epithelial-mesenchymal transition. Mol. Cell Biol. 2001, 21:8184-8188.
32. Mani S.A., Yang J., Brooks M., Schwaninger G., Zhou A., Miura N., Kutok J.L., Hartwell K., Richardson A.L., Weinberg R.A. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10069-10074.
33. Saxena M., Stephens M.A., Pathak H., Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011, 2:e179.
34. Karajannis M.A., Vincent L., Direnzo R., Shmelkov S.V., Zhang F., Feldman E.J., Bohlen P., Zhu Z., Sun H., Kussie P., Rafii S. Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. Leukemia 2006, 20:979-986.
35. Singh S., Srivastava S.K., Bhardwaj A., Owen L.B., Singh A.P. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br. J. Cancer 2010, 103:1671-1679.
36. Bhola N.E., Balko J.M., Dugger T.C., Kuba M.G., Sanchez V., Sanders M., Stanford J., Cook R.S., Arteaga C.L. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 2013, 123:1348-1358.
37. Chen Y., Jacamo R., Konopleva M., Garzon R., Croce C., Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J. Clin. Invest. 2013, 123:2395-2407.
38. Cole C., Lau S., Backen A., Clamp A., Rushton G., Dive C., Hodgkinson C., McVey R., Kitchener H., Jayson G.C. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol. Ther. 2010, 10:495-504.
39. Steelman L.S., Abrams S.L., Shelton J.G., Chappell W.H., Basecke J., Stivala F., Donia M., Nicoletti F., Libra M., Martelli A.M., McCubrey J.A. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle 2010, 9:1629-1638.
40. Balko J.M., Cook R.S., Vaught D.B., Kuba M.G., Miller T.W., Bhola N.E., Sanders M.E., Granja-Ingram N.M., Smith J.J., Meszoely I.M., Salter J., Dowsett M., Stemke-Hale K., Gonzalez-Angulo A.M., Mills G.B., Pinto J.A., Gomez H.L., Arteaga C.L. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 2012, 18:1052-1059.
41. Jiao X., Zhao L., Ma M., Bai X., He M., Yan Y., Wang Y., Chen Q., Zhao X., Zhou M., Cui Z., Zheng Z., Wang E., Wei M. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res. Treat. 2013, 139:717-730.
42. Zhu W., Shan X., Wang T., Shu Y., Liu P. MiR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J. Cancer 2010, 127:2520-2529.
43. Cai J., Yang C., Yang Q., Ding H., Jia J., Guo J., Wang J., Wang Z. Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis 2013, 2:e75.
44. Feng B., Wang R., Chen L.B. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett. 2012, 317:184-191.
45. Jiang L., Huang Q., Chang J., Wang E., Qiu X. MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp. Lung Res. 2011, 37:387-398.
46. Kang J., Lee S.Y., Lee S.Y., Kim Y.J., Park J.Y., Kwon S.J., Na M.J., Lee E.J., Jeon H.S., Son J.W. MicroRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3. Exp. Ther. Med. 2012, 3:149-153.